Acute inactivation of RB1 in hormone-dependent luminal breast and colon cancer cells increases response to several antineoplastic drugs, suggesting that RB-deficiency affects therapeutic outcome in certain tumor types including ER+ breast cancer. This evidence concerns the gene RB1 and breast cancer.